Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Tango Therapeutics in a ...

CVS Health investors will closely examine this week turnaround initiatives spearheaded by new CEO David Joyner and their ...

Leerink raised the firm’s price target on Axsome Therapeutics (AXSM) to $150 from $110 and keeps an Outperform rating on the shares. The ...

Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Alumis Inc. (ALMS – Research Report) and Martin ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Market Perform to Outperform. There are 2,471 funds or institutions ...